Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

Key developments in US health news include the release of new dietary guidelines, FDA approvals for bladder and lung cancer drugs, and significant policy shifts by U.S. Health Secretary Robert F.

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

Three years after litigation started over technology used in Comirnaty, the mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an all-stock transaction valued at ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response rates of up to 90% in patients treated with Ibtrozi for locally advanced or ...

Patience pays off for this biotech deal © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...